Physician profile
Hua C Lu
NPI 1962499897
$2,512.86
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,136 · 2020: $377.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $474.21 | 2019-2020 | |
| Novo Nordisk INC | $281.64 | 2019-2020 | |
| Pfizer INC. | $257.76 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.13 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $203.07 | 2019-2020 | |
| Amgen INC. | $156.43 | 2019 | |
| Lilly USA, LLC | $145.97 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $143.12 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $101.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $61.20 | 2019 | |
| Amarin Pharma, INC. | $55.87 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $47.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.60 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.16 | 2019-2020 | |
| Glaxosmithkline, LLC. | $38.35 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $36.70 | 2019 | |
| Radius Health, INC. | $21.91 | 2020 | |
| Avanir Pharmaceuticals, INC. | $20.25 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $19.84 | 2019 | |
| Astellas Pharma US INC | $19.78 | 2019 | |
| Mylan Specialty L.P. | $18.90 | 2019 | |
| Eisai INC. | $17.29 | 2020 | |
| Sanofi Pasteur INC. | $15.15 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.44 | 2019 | |
| Lupin INC. | $14.12 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.03 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hua Lu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.